Login / Signup

Lewis glycosphingolipids as critical determinants of TRAIL sensitivity in cancer cells.

Tomoya FukuokaKenta MoriwakiShinji TakamatsuJumpei KondoMiki Tanaka-OkamotoAzusa TomiokaManami SembaSachiko Komazawa-SakonYoshihiro KamadaHiroyuki KajiYasuhide MiyamotoMasahiro InoueKazuhiko BesshoYoko MiyoshiKeiichi OzonoHiroyasu NakanoEiji Miyoshi
Published in: Oncogene (2022)
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces cancer cell death and contributes to tumor rejection by cytotoxic lymphocytes in cancer immunosurveillance and immunotherapy. TRAIL and TRAIL receptor agonists have garnered wide popularity as promising agents for cancer therapy. We previously demonstrated that the loss of fucosylation in cancer cells impairs TRAIL sensitivity; however, the precise structures of the fucosylated glycans that regulate TRAIL sensitivity and their carrier molecules remain elusive. Herein, we observed that Lewis glycans among various fucosylated glycans positively regulate TRAIL-induced cell death. Specifically, Lewis glycans on lacto/neolacto glycosphingolipids, but not glycoproteins including TRAIL receptors, enhanced TRAIL-induced formation of the cytosolic caspase 8 complex, without affecting the formation of the membranous receptor complex. Furthermore, type I Lewis glycan expression in colon cancer cell lines and patient-derived cancer organoids was positively correlated with TRAIL sensitivity. These findings provide novel insights into the regulatory mechanism of TRAIL-induced cell death and facilitate the identification of novel predictive biomarkers for TRAIL-related cancer therapies in future.
Keyphrases